查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179908

2023-2030 年全球膠質母細胞瘤治療市場

Global Glioblastoma Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

膠質母細胞瘤也稱為多形性膠質母細胞瘤 (GBM)。 膠質母細胞瘤是一種在大腦和脊髓中形成的侵襲性癌症。 膠質母細胞瘤由支持神經細胞的稱為星形膠質細胞的細胞形成。 膠質母細胞瘤可以發生在任何年齡，但它往往更常發生在老年人身上。 治療包括放療、化療和手術。

市場動態

政府和非政府組織正在努力提高人們對多形性膠質母細胞瘤的認識。 主要參與者的強大研發計劃、多形性膠質母細胞瘤發病率上升以及美國 FDA 批准的新藥增加是預測期內推動市場的因素。

世界各地的政府和非政府組織採取各種努力，通過教育多形性膠質母細胞瘤患者來提高認識，這有望推動市場增長。

移動消息平台 Ping Mobile 發起了一項移動活動，以提高人們對腦癌的認識。 這有助於提高人們對多形性膠質母細胞瘤的認識，並激勵人們為多形性膠質母細胞瘤的研究工作捐款。 此外，美國腦腫瘤協會、加拿大腦腫瘤基金會和治愈腦癌基金會等組織也在做很多宣傳工作，以提高公眾對該病的認識。 在英國，三月是“腦腫瘤宣傳月”，腦腫瘤研究的成員慈善機構發起了一項活動。 該活動的主要目的是提高人們對腦腫瘤研究資金短缺的認識，並提高人們對腦腫瘤及其治療方法的認識。 Novocure 還在腦腫瘤宣傳月期間開展了一場關於多形性膠質母細胞瘤的宣傳活動。 這些因素正在推動預測期內的市場增長。

與治療多形性膠質母細胞瘤相關的高成本是抑制市場增長的主要因素。

商業保險患者接受 TMZ 治療的新診斷 GBM 的直接醫療費用很高，估計為 268,031 美元。 已經進行了廣泛的研究以減少與膠質母細胞瘤患者護理相關的直接成本。 直接成本是歸因於疾病的成本，例如與疾病的所有相關治療和管理相關的成本，由各方（包括患者）承擔，取決於保險狀況等因素。存在這種可能性。 大部分直接費用發生在治療的前四個月，費用穩定超過一年，反映出這種疾病的生存率很低。 放射和手術對 GBM 的直接成本貢獻最大。 因此，預計上述因素將在預測期內阻礙市場。

COVID-19 影響分析

一般而言，癌症患者和膠質母細胞瘤患者發生嚴重急性呼吸系統綜合症冠狀病毒2型（SARS-CoV-2）並發症的風險高，感染風險和治療的臨床療效都很高。一個平衡點是理想的。 該腫瘤組的侵襲性行為證明需要一個多學科團隊來支持當前大流行期間的臨床決策。 COVID-19 在實體瘤發生中的作用尚不清楚，也未見在神經膠質瘤病理生理學中的作用的報導。 已知神經膠質細胞和神經元在其表面表達 ACE2，神經元可能是 COVID-19 的感染目標。

當前的高級別膠質瘤 (HGG) 治療指南提供了一個基於證據的護理框架，以改善無進展生存期和總生存期 (OS)。 在大流行期間，醫生必須平衡弱勢人群感染 COVID-19 的風險與癌症患者治療不足的風險。 此外，社會需要保護醫護人員並避免二次病毒傳播給患者。 對於大多數神經腫瘤中心來說，在 COVID-19 大流行期間接觸到膠質母細胞瘤患者是很困難的。 巴西各州之間的醫療差異使醫生難以做出適當的治療決定。 具有良好體能狀態和分子特徵的患者應接受標準治療方案，包括切除和同步放化療的最安全組合。

老年患者和體能狀態不佳的患者應謹慎治療，並應在 COVID-19 流行期間單獨使用，除非體能狀態良好的無並發症患者受益於替莫唑胺大分割方案。藥物治療方案似乎是最合適的. 當前形勢對提供最佳醫療保健提出了新的挑戰，找到與患者溝通的新方式至關重要。 然而，這種情況預計將在預測期內逐漸改善。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第4章市場動態

  • 市場影響因素
    • 司機
      • 通過世界各地政府和非政府組織開展的各種努力，通過教育多形性膠質母細胞瘤患者提高認識，預計將推動市場增長。
    • 約束因素
      • 與治療多形性膠質母細胞瘤相關的高成本是限制市場增長的主要因素。
    • 市場機會
    • 影響分析

第五章行業分析

  • 搬運工的五種力量
  • 供應鏈
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型分類

  • 化療
    • 替莫唑胺
    • 貝伐單抗
    • 卡莫司汀
    • 其他
  • 免疫療法
  • 電場療法
  • 其他

第 8 章分子類型

  • 低分子化合物
  • 生物製品

第9章給藥途徑

  • 口語
  • 腸外

第 10 章最終用戶

  • 醫院
  • 診所
  • 其他

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第13章公司簡介

  • 基因泰克
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Amgen
  • Merck & Co., Inc
  • Teva Pharmaceutical Industries, Ltd.
  • Arbor Pharmaceuticals LLC
  • Sun Pharmaceutical Industries, Ltd.
  • F. Hoffman-La Roche
  • Novartis AG
  • Pfizer

第14章 全球膠質母細胞瘤治療市場-DataM

簡介目錄
Product Code: DMPH3059

Market Overview

The global glioblastoma treatment market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Glioblastoma is also known as glioblastoma multiforme (GBM). Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells. Glioblastoma can occur at any age but tends to occur more often in older adults. Treatments include radiation, chemotherapy and surgery.

Market Dynamics

Governments and non-government bodies undertake various initiatives to raise awareness about glioblastoma multiforme. Strong R&D Initiatives from key players, rising incidence of glioblastoma multiforme and increasing US FDA approval of new drugs are the factors to drive the market in the forecast period.

Increasing awareness by educating people living with glioblastoma multiforme through various initiatives undertaken by governments and non-government bodies across the globe is expected to drive market growth.

Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps raise awareness about glioblastoma multiforme and motivates people to donate money for glioblastoma multiforme research activities. Moreover, organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The campaign's main aim is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Additionally, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month. These factors are driving the growth of the market in the forecast period.

The high cost associated with treating the glioblastoma multiforme is a major factor that hampers the market growth.

The direct medical costs of newly diagnosed TMZ-treated GBM in commercially insured patients are substantial, with estimated costs of $268,031. Extensive studies have been conducted to decrease the direct costs associated with care for patients with glioblastoma. Direct costs are those attributable to the disease, including all the associated therapies and costs associated with managing the disease, which may be borne by various parties (including the patient), depending on factors such as insurance status. The majority of direct costs were incurred in the first four months of treatment, with a plateau in costs beyond one year, reflecting the poor survival of this disease. Radiation and surgery contribute most to the direct costs of GBM. Thus, from the above factors, the market is expected to be hampered in the forecast period.

COVID-19 Impact Analysis

Cancer patients, in general, and glioblastoma patients, are at a higher risk of developing complications from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and striking a balance between the risk of infection and the clinical benefit of treatment is ideal. This group of tumors' aggressive behavior justifies the need for a multidisciplinary team to assist in clinical decisions during the current pandemic. COVID-19's role in the tumorigenesis of solid cancer is unknown, and its role in glioma pathophysiology has not been reported. Glial and neuronal cells are known to express ACE2 on their surfaces, making neuronal cells a potential target for COVID-19 infection.

The current high-grade glioma (HGG) treatment guidelines provide an evidence-based care framework to improve progression-free and overall survival (OS). During the pandemic, doctors must strike a balance between the risks of COVID-19 in a vulnerable population and the risk of under-treatment cancer patients. Furthermore, there is a societal need for healthcare workers to be protected and for secondary viral spread to patients to be avoided. Approaching glioblastoma patients during the COVID-19 pandemic is difficult in most neuro-oncology centers. Significant healthcare disparities between Brazilian states make it difficult for physicians to make appropriate treatment decisions. Patients with good performance status and molecular profile should receive the standard treatment protocol, including the safest resection and concurrent chemo-radiotherapy.

Older patients and those with poor performance status should be treated with caution, and a monotherapy regimen may be best suited during the COVID-19 pandemic unless patients with good performance status and no comorbidities benefit from hypofractionated protocols with temozolomide. The current situation adds new challenges to providing the best healthcare possible, and finding new ways to communicate with patients is critical. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Chemotherapy segment is expected to hold the largest market share in glioblastoma treatment market

Glioblastoma multiforme (GBM) is adults' most common primary brain tumor. No specific medications exist to treat GBM. However, certain conditions require medical treatment. For seizures, the patient usually is started on levetiracetam (Keppra), phenytoin (Dilantin), or carbamazepine (Tegretol). Levetiracetam is often used because it lacks the effects on the P450 system seen with phenytoin and carbamazepine, which can interfere with antineoplastic therapy. Chemotherapy is a common type of treatment for glioblastoma multiforme. Most patients begin chemotherapy two to four weeks after surgery, concurrently or shortly after radiation therapy. Chemotherapy is sometimes the primary treatment when a tumor cannot be surgically removed. It works by using powerful medications to destroy rapidly dividing cancer cells. These medications can be taken as pills, injected into a vein, or, in some cases, injected into the intrathecal space of the spine.

Chemotherapy for glioblastoma requires a high level of expertise because tumors are frequently made up of multiple types of cells. Some medications may kill some of these cells while allowing others to proliferate unhindered. As a result, medical oncologists must carefully tailor treatment plans for glioblastoma patients. These factors will drive the segment's growth during the forecast period. Efforts to develop new treatments have focused on discovering new drug targets and categorizing patients based on age and molecular cancer markers. Immunotherapy, RIT, or dietary treatments combined with standard radio(chemo)therapy are other promising research avenues currently in translational development. Patients undergoing chemotherapy are given drugs that are designed to kill tumor cells. The current gold standard of treatment for GBM is chemotherapy with temozolomide. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global glioblastoma treatment market

North America region accounted for the largest market share in 2021. Owing to significant market players, increasing healthcare awareness, and FDA approvals for novel drugs and the development of advanced treatment methods that counter glioma stem cells' resistive properties are also positively influencing market growth. Additionally, increasing research and development (R & R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated various biological drugs. These drugs assist in diminishing the side effects of the existing treatment methods, thus creating broader acceptance amongst patients. New drug approvals and launches for GBM treatment are expected to drive market growth in the region. For instance, in January 2020, Pfizer launched 'Zirabev' in the U.S. It is a bevacizumab biosimilar to Avastin, approved for treating recurrent glioblastoma multiforme.

Additionally, On April 09, 2021, Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM). Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the glioblastoma treatment market are Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries, Ltd., F. Hoffman-La Roche, Novartis AG and Pfizer.

On April 09, 2021, Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM).

Genentech Inc.:

Overview:

Genentech Inc. is a biotechnology company based in the United States that became a subsidiary of Roche in 2009. The company is dedicated to pioneering science to discover and develop medicines for people suffering from serious and life-threatening diseases. In the United States, Roche and Genentech merged their pharmaceutical operations. The Genentech campus in South San Francisco is now the headquarters for Roche's pharmaceutical operations in the United States. Genentech Research and Early Development is a separate entity within Roche. Roche Holding Ltd. owns 66 percent of Genentech but allows it to operate independently. Genentech discovers, develops, manufactures, and sells human pharmaceuticals to meet critical medical needs.

Product Portfolio:

Avastin (bevacizumab): Avastin (bevacizumab) is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

The global glioblastoma treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. arket Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness by educating people living with glioblastoma multiforme through various initiatives undertaken by governments and non-government bodies across the globe is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost associated with treating the glioblastoma multiforme is a major factor that hampers the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Chemotherapy*
      • 7.2.1.1. Temozolomide
      • 7.2.1.2. Introduction
      • 7.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.2.1.4. Bevacizumab
      • 7.2.1.5. Carmustine
      • 7.2.1.6. Others
  • 7.3. Immunotherapy
  • 7.4. Electric-field therapy
  • 7.5. Others

8. By Type of Molecule

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 8.1.2. Market Attractiveness Index, By Type of Molecule
  • 8.2. Small Molecules*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biologics

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Parenteral

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user
  • 10.2. Hospitals*
      • 10.2.1.1. Introduction
      • 10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Genentech*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Amgen
  • 13.3. Merck & Co., Inc
  • 13.4. Teva Pharmaceutical Industries, Ltd.
  • 13.5. Arbor Pharmaceuticals LLC
  • 13.6. Sun Pharmaceutical Industries, Ltd.
  • 13.7. F. Hoffman-La Roche
  • 13.8. Novartis AG
  • 13.9. Pfizer

LIST NOT EXHAUSTIVE

14. Global Glioblastoma Treatment Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us